39394148|t|NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's disease via ATF4-dependent mitochondrial UPR.
39394148|a|Extensive studies indicate that mitochondria dysfunction is pivotal for Alzheimer's disease (AD) pathogenesis; while cumulative evidence suggests that increased mitochondrial stress response (MSR) may mitigate neurodegeneration in AD, explorations to develop a MSR-targeted therapeutic strategy against AD are scarce. We combined cell biology, molecular biology, and pharmacological approaches to unravel a novel molecular pathway by which NAD+-boosting agent nicotinamide mononucleotide (NMN) regulates MSR in AD models. Here, we report dyshomeostasis plasma UPRmt-mitophagy-mediated MSR profiles in AD patient samples. NMN restores NAD+ metabolic profiles and improves MSR through the ATF4-dependent UPRmt pathway in AD-related cross-species models. At the organismal level, NAD+ repletion with NMN supplementation ameliorates mitochondrial proteotoxicity, decreases hippocampal synaptic disruption, decreases neuronal loss, and brain atrophy in mice model of AD. Remarkably, omics features of the hippocampus with NMN show that NMN leads to transcriptional changes of genes and proteins involved in MSR characteristics, principally within the astrocyte unit rather than microglia and oligodendrocytes. In brief, our work provides evidence that MSR has an active role in the pathogenesis of AD, as reducing mitochondrial homeostasis via atf4 depletion in AD mice aggravates the hallmarks of the disease; conversely, bolstering mitochondrial proteostasis by NMN decreases protein aggregation, restores memory performance, and delays disease progression, ultimately translating to increased healthspan.
39394148	0	4	NAD+	Chemical	MESH:D009243
39394148	20	47	nicotinamide mononucleotide	Chemical	MESH:D009537
39394148	98	117	Alzheimer's disease	Disease	MESH:D000544
39394148	122	126	ATF4	Gene	468
39394148	188	212	mitochondria dysfunction	Disease	MESH:C564971
39394148	228	247	Alzheimer's disease	Disease	MESH:D000544
39394148	249	251	AD	Disease	MESH:D000544
39394148	366	383	neurodegeneration	Disease	MESH:D019636
39394148	387	389	AD	Disease	MESH:D000544
39394148	459	461	AD	Disease	MESH:D000544
39394148	596	600	NAD+	Chemical	MESH:D009243
39394148	616	643	nicotinamide mononucleotide	Chemical	MESH:D009537
39394148	645	648	NMN	Chemical	MESH:D009537
39394148	667	669	AD	Disease	MESH:D000544
39394148	757	759	AD	Disease	MESH:D000544
39394148	760	767	patient	Species	9606
39394148	777	780	NMN	Chemical	MESH:D009537
39394148	790	794	NAD+	Chemical	MESH:D009243
39394148	843	847	ATF4	Gene	468
39394148	875	877	AD	Disease	MESH:D000544
39394148	933	937	NAD+	Chemical	MESH:D009243
39394148	953	956	NMN	Chemical	MESH:D009537
39394148	985	1013	mitochondrial proteotoxicity	Disease	MESH:D028361
39394148	1068	1081	neuronal loss	Disease	MESH:D009410
39394148	1087	1100	brain atrophy	Disease	MESH:C566985
39394148	1104	1108	mice	Species	10090
39394148	1118	1120	AD	Disease	MESH:D000544
39394148	1173	1176	NMN	Chemical	MESH:D009537
39394148	1187	1190	NMN	Chemical	MESH:D009537
39394148	1449	1451	AD	Disease	MESH:D000544
39394148	1495	1499	atf4	Gene	468
39394148	1513	1515	AD	Disease	MESH:D000544
39394148	1516	1520	mice	Species	10090
39394148	1615	1618	NMN	Chemical	MESH:D009537
39394148	Positive_Correlation	MESH:D009243	MESH:C566985
39394148	Negative_Correlation	MESH:D009537	MESH:D028361
39394148	Negative_Correlation	MESH:D009537	MESH:D009410
39394148	Association	MESH:D000544	468
39394148	Association	MESH:D009537	MESH:D000544
39394148	Negative_Correlation	MESH:D009537	MESH:C566985
39394148	Association	MESH:D009243	MESH:D028361
39394148	Association	MESH:D009537	468
39394148	Cotreatment	MESH:D009243	MESH:D009537
39394148	Positive_Correlation	MESH:D009243	MESH:D009410

